secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-086658
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports 2025 net loss $29.6M; cash $13M; KOURAGE safety review finds no drug toxicity
--------------------------------------------------------------------------------

- Net loss $29.6M ($1.97/share) vs $13.7M ($1.22/share) in 2024; R&D expense $15.2M, G&A $7.9M.
- Cash, equivalents & short-term investments $13.0M as of Dec 31, 2025; expected to fund operations into Q4 2026.
- KOURAGE trial in AKI discontinued; internal & external safety review found no evidence of drug-related toxicity.
- Pivotal program design for Auxora in acute pancreatitis expected 1H 2026 following constructive FDA engagement.
- CM5480 for PAH: IND submission anticipated in 2027; preclinical data published in JCI Insight.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/0001193125-26-086658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/ck0001534133-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-086658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer